Company: BIAF
Filing Date: 2025-06-27
Form Type: POS AM
Source: 0001641172-25-016927
Chunk: 193

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-06-27
Form: POS AM
Chunk 193
---
 |    2024 |
|:---------------------------------------|:----|:-------------------|--------:|:----|:-----|--------:|
| Research and development               |     | $                  |  21,250 |     | $    |  21,882 |
| General and administrative             |     |                    | 305,366 |     |      | 260,731 |
| Total stock-based compensation expense |     | $                  | 326,616 |     | $    | 282,613 |

The
following table summarizes stock option activity under the 2014 Plan and 2024 Plan:

SUMMARY OF OPTION ACTIVITY

|                                          |     | Number of 
 options   |         |     | Weighted-average 
 exercise price   |      |     | Weighted-average      
 remaining contractual 
 term                  
 (in years)            |      |     | Aggregate       
 intrinsic value |   |
|:-----------------------------------------|:----|:----------|--------:|:----|:-----------------|-----:|:----|:----------------------|-----:|:----|:----------------|:--|
| Outstanding at December 31, 2024         |     |           | 304,125 |     | $                | 6.95 |     |                       | 4.45 |     |                 | — |
| Granted                                  |     |           |       — |     |                  |    — |     |                       |    — |     |                 | — |
| Exercised                                |     |           |       — |     |                  |    — |     |                       |    — |     |                 | — |
| Forfeited                                |     |           |       — |     |                  |    — |     |                       |    — |     |                 | — |
| Outstanding at March 31, 2025            |     |           | 304,125 |     | $                | 6.95 |     |                       | 4.20 |     |                 | — |
| Vested and exercisable at March 31, 2025 |     |           | 304,125 |     | $                | 6.95 |     |                       | 4.20 |     |                 | — |

| F-13 |

As of March 31, 2025, there was no
unrecognized compensation cost related to non-vested stock options.

The
following table summarizes restricted stock award activity under